Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sunobinop in Overactive Bladder Syndrome
NCT06024642Phase 1Completed
- Sponsor
- Imbrium Therapeutics
- Start
- Jun 2022
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of sunobinop in overactive bladder syndrome (OAB) (2 arms), sponsored by Imbrium Therapeutics. Primary endpoint: Change From Baseline in Micturition Episode Components Per 24 Hours at 8 weeks. Started Jun 2022; status: completed.
02
Drugs
sunobinop
03
Conditions
overactive bladder syndrome (OAB)
Beyond the preview
Go deeper on NCT06024642.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06024642.